VCRE (Vicore Pharma Holding AB) Cash Payments


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $15.60
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

VCRE
13GF Score
Vicore Pharma Holding AB VCRE
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.60
Price